Lebanon, NHNCT07043270Now EnrollingIRB Ready

Pancreas Adenocarcinoma Clinical Trial in Lebanon, NH

Access cutting-edge pancreas adenocarcinoma treatment through this phase 2 clinical trial at a research site in Lebanon. Study-provided care at no cost to qualified participants.

Sponsored by Dartmouth-Hitchcock Medical Center

Quick Self-Assessment

See if you qualify for this Lebanon location

Preparing your pre-screening questions…

Expert Care in Lebanon

Access pancreas adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreas adenocarcinoma treatment provided free

Apply for This Lebanon Location

Check if you qualify for this pancreas adenocarcinoma clinical trial in Lebanon, NH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lebanon

    Convenient for NH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lebanon site if eligible
  4. 4Begin participation

About This Pancreas Adenocarcinoma Study in Lebanon

The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.

Sponsor: Dartmouth-Hitchcock Medical Center

Who Can Participate

Inclusion Criteria

Age ≥ 18 years
Diagnosis of BR-PDAC. The resectability should be officially determined with surgical oncologists at the Dartmouth Cancer Center (DCC) GI multidisciplinary Tumor Board based on NCCN Guidelines Version 2.2024 Pancreatic Adenocarcinoma.
Patients must be able and willing to provide informed consent.
Contrast-enhanced CT scan of the chest, abdomen, and pelvis performed within 45 days before registration.
ECOG Performance Status: 0-1.
Females of childbearing potential must have a negative pregnancy test done ≤ 14 days prior to study enrollment, and must agree to use a highly effective method of contraception throughout the course of protocol therapy.

Exclusion Criteria

Any prior receipt of chemotherapy or radiation therapy for PDAC.
Known DPYD poor metabolizer genotype.
Known BRCA1/2 or PALB2 mutations. If they are found to have BRCA1/2 or PALB2 mutation after inclusion to the trial, the participant will be taken off of protocol therapy (since platinum-containing therapy is preferred for these patients).
Any confirmed second malignancy that is likely to require systemic therapy during the study period, in the opinion of the enrolling investigator.
Any of the following baseline laboratory abnormalities:
Absolute neutrophil count (ANC) \< 2,500/mm3
Platelet count \< 100,000/mm3
Hemoglobin \< 7 g/dL
Creatinine \> 1.5 x upper limit of normal (ULN)
Total bilirubin \> 1.5 x ULN
AST/ALT \> 5 x ULN
Any peripheral sensory neuropathy that meaningfully impairs performance of instrumental activities of daily living, as evaluated by the enrolling investigator.
Patients who are unable to provide informed consent.
Patients who are pregnant or breastfeeding.
Patients who are incarcerated.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lebanon?

Yes, this clinical trial (NCT07043270) has an active research site in Lebanon, NH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreas Adenocarcinoma Treatment Options in Lebanon, NH

If you're searching for pancreas adenocarcinoma treatment options in Lebanon, NH, this clinical trial (NCT07043270) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lebanon research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced pancreas adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreas adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Lebanon, NH

See all alzheimers disease clinical trials recruiting in Lebanon — not just this study.

Browse Alzheimers Disease Trials in Lebanon →

Browse More Trials by Condition

Alzheimers Disease TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Lebanon?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lebanon, NH